Positrigo's brain scanner has been approved for a clinical trial

(CONNECT) NeuroLF, Positrigo’s positron emission tomography (PET) system for the brain, will play a key role in a clinical study conducted by Ludwig Maximilian University of Munich (LMU). According to a press release from the company, which is based at Technopark Zurich, the brain scanner was approved by the sponsor for this Phase 2 study. It is performed on adults with early-stage Alzheimer's disease associated with Down syndrome.

“We are pleased that a leading sponsor of clinical trials has officially accepted NeuroLF as the imaging platform for its research project,” Dr. Dr. med. Matthias Brendel is quoted as saying. He is a professor of translational molecular imaging at LMU, a senior physician in neuronuclear medicine, and the associate director of the Department of Nuclear Medicine. "This is an important step toward expanding the use of specialised PET imaging of the brain in clinical research, and we plan to consider using NeuroLF—wherever appropriate—for further studies at LMU as well."

Positrigo describes this study approval as another important milestone for the company, which was spun off from the Swiss Federal Institute of Technology Zurich in 2018. Ultimately, however, according to Positrigo co-founder and CEO Dr. Jannis Fischer, the mission goes beyond research: “We are committed to making modern PET imaging of the brain widely available in routine clinical practice so that more patients can benefit from earlier and more precise diagnoses. With the availability of new disease-modifying therapies, timely molecular diagnosis will be crucial to ensuring that patients receive the appropriate treatment at the right time.” NeuroLF has already been approved by regulatory authorities in the EU and the U.S. ce/mm